{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:24:08Z","timestamp":1772213048662,"version":"3.50.1"},"reference-count":12,"publisher":"Baishideng Publishing Group Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Psychiatry"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n                  <jats:p>Proper antidepressant use can improve mood and reduce desire to drink alcohol in alcohol-induced-affective-disorder patients. Shugan Jieyu capsules (SJC) have various impacts on the central nervous system, producing antidepressant effects. Traditional Chinese medicine (including Shugan Jieyu) is highly therapeutic in treating alcohol dependence, with few side-effects. However, research on its combination with Western antidepressants (e.g.,  sertraline) to improve patients\u2019 depression is insufficient.<\/jats:p>\n                  <jats:p>AIM<\/jats:p>\n                  <jats:p>To evaluate the clinical efficacy and safety of SJC combined with sertraline vs  sertraline monotherapy in alcohol-dependent patients with comorbid depression.<\/jats:p>\n                  <jats:p>METHODS<\/jats:p>\n                  <jats:p>We conducted a randomized, double-blind, placebo-controlled trial. Sixty patients (aged 18-65 years) were randomly assigned to two groups (n  = 30 per group). Primary outcome: Hamilton Depression Rating Scale (HAMD)-17 changes over 6 weeks. Benzodiazepines were permitted for severe insomnia.<\/jats:p>\n                  <jats:p>RESULTS<\/jats:p>\n                  <jats:p>The HAMD-17 score of the study (vs  control) group was lower at treatment weeks 2, 4, and 6 (P  &lt; 0.05). Regarding intra-group comparisons, the study group\u2019s HAMD score was significantly lower than that before treatment from week 2 (P  &lt; 0.05), while that of the control group was significantly lower than that before treatment from week 4 (P  &lt; 0.05). The study and control groups\u2019 total efficacy rates were 90% and 73.3%, respectively, showing a significant difference in efficacy (\u03c7\u00b2  = 4.812, P  = 0.028). No significant difference was observed in adverse reactions\u2019 incidence between the groups at treatment weeks 2, 4, and 6 (P  &gt; 0.05).<\/jats:p>\n                  <jats:p>CONCLUSION<\/jats:p>\n                  <jats:p>SJC-sertraline combination therapy accelerates depressive symptom relief (by 2 weeks) and improves response rates (+16.7%) in alcohol-dependent patients, without increasing adverse events. Clinical outcomes suggest potential synergistic mechanisms, though no biomarker analyses were performed.<\/jats:p>","DOI":"10.5498\/wjp.v15.i12.111801","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:37:38Z","timestamp":1764063458000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and mechanism of Shugan Jieyu combined with sertraline in alcohol-dependent patients with depression: A randomized clinical study"],"prefix":"10.5498","volume":"15","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Yu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3110"},{"key":"B2","unstructured":"Liu HQ, Hong ML, Fang T, Cai HC. [Clinical on sertraline hydrochloride tablet combined with Shugan Jieyu capsule in patients with post-stroke depression and sleep disorders]. Xizang Yiyao 2023; 13-15"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.13936\/j.cnki.cjdd1992.2021.05.003"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-9346.2016.05.012"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agr027"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.alcohol.2025.06.004"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/add.16769"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.04.002"},{"key":"B9","unstructured":"Shen YC.   Psychiatry. 4th ed. Beijing: People\u2019s Medical Publishing House, 2005"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-9463.2013.04.012"},{"key":"B11","unstructured":"Zhang YF, Ma CL, Ge XF, Wen Y, Yang XL, Feng J. [Clinical study of Shugan Jieyu capsule combined with buspirone hydrochloride tablets and sertraline hydrochloride dispersible tablets on Alzheimer\u2019s disease with depression and anxiety disorder]. Hebei Zhongyi 2018; 1166-1170"},{"key":"B12","unstructured":"Zhang MY, He YL.   Manual of psychiatric rating scale. Hunan: Hunan Science and Technology Press, 2015"}],"container-title":["World Journal of Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v15\/i12\/111801.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v15\/i12\/111801.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:38:30Z","timestamp":1764063510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v15\/i12\/111801.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":12,"journal-issue":{"issue":"12"},"alternative-id":["111801"],"URL":"https:\/\/doi.org\/10.5498\/wjp.v15.i12.111801","relation":{},"ISSN":["2220-3206"],"issn-type":[{"value":"2220-3206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}